Predictive Value of K_i-67 Index in Evaluating Sporadic Vestibular Schwannoma Recurrence: Systematic Review and Meta-analysis

Abstract

Introduction K_i-67 is often used as a proliferation index to evaluate how aggressive a tumor is and its likelihood of recurrence. Vestibular schwannomas (VS) are a unique benign pathology that lends itself well to evaluation with K_i-67 as a potential marker for disease recurrence or progression following surgical resection.

Methods All English language studies of VSs and K_i-67 indices were screened. Studies were considered eligible for inclusion if they reported series of VSs undergoing primary resection without prior irradiation, with outcomes including both recurrence/progression and K_i-67 for individual patients. For published studies reporting pooled K_i-67 index data without detailed by-patient values, we contacted the authors to request data sharing for the current meta-analysis. Studies reporting a relationship between K_i-67 index and clinical outcomes in VS for which detailed patients' outcomes or K_i-67 indices could not be obtained were incorporated into the descriptive analysis, but excluded from the formal (i.e., quantitative) meta-analysis.

Results A systematic review identified 104 candidate citations of which 12 met inclusion criteria. Six of these studies had accessible patient-specific data. Individual patient data were collected from these studies for calculation of discrete study effect sizes, pooling via random-effects modeling with restricted maximum likelihood, and meta-analysis. The standardized mean difference in K_i-67 indices between those with and without recurrence was calculated as 0.79% (95% confidence interval [CI]: 0.28–1.30; p = 0.0026).

Conclusion K_i-67 index may be higher in VSs that demonstrate recurrence/progression following surgical resection. This may represent a promising means of evaluating tumor recurrence and potential need for early adjuvant therapy for VSs.

Keywords

histopathology - vestibular schwannoma - acoustic neuroma - recurrence - progression - K_i-67 - index - systematic review - meta-analysis

Publication History

Received: 23 June 2021

Accepted: 31 January 2022

Accepted Manuscript online:
03 February 2022

Article published online:
03 March 2022

• References

• 1 Nakatomi H, Jacob JT, Carlson ML. et al. Long-term risk of recurrence and regrowth after gross-total and subtotal resection of sporadic vestibular schwannoma. J Neurosurg 2017; May 19; 1-7
• 2 Iannella G, de Vincentiis M, Di Gioia C. et al. Subtotal resection of vestibular schwannoma: evaluation with Ki-67 measurement, magnetic resonance imaging, and long-term observation. J Int Med Res 2017; 45 (03) 1061-1073
• 3 Jacob JT, Carlson ML, Driscoll CL, Link MJ. Volumetric analysis of tumor control following subtotal and near-total resection of vestibular schwannoma. Laryngoscope 2016; 126 (08) 1877-1882
• 4 Choi Y, Lim DH, Yu JI. et al. Prognostic value of Ki-67 labeling index and postoperative radiotherapy in WHO grade II meningioma. Am J Clin Oncol 2018; 41 (01) 18-23
• 5 Liu N, Song SY, Jiang JB, Wang TJ, Yan CX. The prognostic role of Ki-67/MIB-1 in meningioma: a systematic review with meta-analysis. Medicine (Baltimore) 2020; 99 (09) e18644
• 6 Mirian C, Skyrman S, Bartek Jr. J. et al. The Ki-67 proliferation index as a marker of time to recurrence in intracranial meningioma. Neurosurgery 2020; 87 (06) 1289-1298
• 7 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372 (71) n71
• 8 Barili F, Parolari A, Kappetein PA, Freemantle N. Statistical primer: heterogeneity, random- or fixed-effects model analyses?. Interact Cardiovasc Thorac Surg 2018; 27 (03) 317-321
• 9 Cafer S, Bayramoglu I, Uzum N, Yilmaz M, Memis L, Uygur K. Expression and clinical significance of Ki-67, oestrogen and progesterone receptors in acoustic neuroma. J Laryngol Otol 2008; 122 (02) 125-127
• 10 Charabi S, Engel P, Jacobsen GK, Tos M, Thomsen J. Growth rate of acoustic neuroma expressed by Ki-67 nuclear antigen versus symptom duration. Ann Otol Rhinol Laryngol 1993; 102 (10) 805-809
• 11 Gomez-Brouchet A, Delisle MB, Cognard C. et al. Vestibular schwannomas: correlations between magnetic resonance imaging and histopathologic appearance. Otol Neurotol 2001; 22 (01) 79-86
• 12 Graffeo CS, Perry A, Raghunathan A. et al. Macrophage density predicts facial nerve outcome and tumor growth after subtotal resection of vestibular schwannoma. J Neurol Surg B Skull Base 2018; 79 (05) 482-488
• 13 Hwang SK, Kim DG, Paek SH. et al. Aggressive vestibular schwannomas with postoperative rapid growth: clinicopathological analysis of 15 cases. Neurosurgery 2002; 51 (06) 1381-1390 , discussion 1390–1391
• 14 Jabbour J, Earls P, Biggs N, Gracie G, Fagan P, Bova R. Role of cyclins D1 and D3 in vestibular schwannoma. J Laryngol Otol 2016; 130 (Suppl. 01) S2-S10
• 15 Lesser TH, Janzer RC, Kleihues P, Fisch U. Clinical growth rate of acoustic schwannomas: correlation with the growth fraction as defined by the monoclonal antibody ki-67. Skull Base Surg 1991; 1 (01) 11-15
• 16 Niemczyk K, Vaneecloo FM, Lecomte MH. et al. Correlation between Ki-67 index and some clinical aspects of acoustic neuromas (vestibular schwannomas). Otolaryngol Head Neck Surg 2000; 123 (06) 779-783
• 17 Panigrahi M, Kumar D, Vooturi S, Madigubba S. MIB index as predictor of recurrence in sporadic vestibular schwannomas. World Neurosurg 2018; 120: e1203-e1207
• 18 Prueter J, Norvell D, Backous D. Ki-67 index as a predictor of vestibular schwannoma regrowth or recurrence. J Laryngol Otol 2019; 133 (03) 205-207
• 19 Steinhart H, Wigand ME, Fahlbusch R, Triebswetter F, Gress H, Iro H. Facial nerve schwannoma in the inner auditory canal and geniculate ganglion [in German]. HNO 2003; 51 (08) 640-645
• 20 Yokoyama M, Matsuda M, Nakasu S, Nakajima M, Handa J. Clinical significance of Ki-67 staining index in acoustic neurinoma. Neurol Med Chir (Tokyo) 1996; 36 (10) 698-702 , discussion 702–703
• 21 Kim YJ, Romeike BF, Uszkoreit J, Feiden W. Automated nuclear segmentation in the determination of the Ki-67 labeling index in meningiomas. Clin Neuropathol 2006; 25 (02) 67-73
• 22 Breivik CN, Varughese JK, Wentzel-Larsen T, Vassbotn F, Lund-Johansen M. Conservative management of vestibular schwannoma–a prospective cohort study: treatment, symptoms, and quality of life. Neurosurgery 2012; 70 (05) 1072-1080 , discussion 1080
• 23 Breshears JD, Chang J, Molinaro AM. et al. Temporal dynamics of pseudoprogression after gamma knife radiosurgery for vestibular schwannomas-a retrospective volumetric study. Neurosurgery 2019; 84 (01) 123-131
• 24 Myrseth E, Møller P, Pedersen PH, Lund-Johansen M. Vestibular schwannoma: surgery or gamma knife radiosurgery? A prospective, nonrandomized study. Neurosurgery 2009; 64 (04) 654-661 , discussion 661–663
• 25 Jacob JT, Pollock BE, Carlson ML, Driscoll CL, Link MJ. Stereotactic radiosurgery in the management of vestibular schwannoma and glomus jugulare: indications, techniques, and results. Otolaryngol Clin North Am 2015; 48 (03) 515-526
• 26 Carlson ML, Jacob JT, Pollock BE. et al. Long-term hearing outcomes following stereotactic radiosurgery for vestibular schwannoma: patterns of hearing loss and variables influencing audiometric decline. J Neurosurg 2013; 118 (03) 579-587
• 27 Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31 (01) 13-20
• 28 Ueda T, Aozasa K, Tsujimoto M. et al. Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer 1989; 63 (08) 1607-1611
• 29 Kontorinis G, Crowther JA, Iliodromiti S, Taylor WA, Locke R. Neutrophil to lymphocyte ratio as a predictive marker of vestibular schwannoma growth. Otol Neurotol 2016; 37 (05) 580-585
• 30 Liu X, Feng M, Zhang Y. et al. Expression of Matrix metalloproteinase-9, pituitary tumor transforming gene, high mobility group A 2, and Ki-67 in adrenocorticotropic hormone-secreting pituitary tumors and their association with tumor recurrence. World Neurosurg 2018; 113: e213-e221
• 31 Hannan CJ, Lewis D, O'Leary C. et al. The inflammatory microenvironment in vestibular schwannoma. Neurooncol Adv 2020; 2 (01) a023
• 32 Lewis D, Roncaroli F, Agushi E. et al. Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma. Neuro-oncol 2019; 21 (03) 314-325
• 33 Nielsen LAG, Bangsø JA, Lindahl KH. et al. Evaluation of the proliferation marker Ki-67 in gliomas: Interobserver variability and digital quantification. Diagn Pathol 2018; 13 (01) 38
• 34 Vörös A, Csörgő E, Nyári T, Cserni G. An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications. Pathobiology 2013; 80 (03) 111-118
• 35 Furukawa T, Ozaka M, Takamatsu M. et al. Ki-67 labeling index variability between surgically resected primary and metastatic hepatic lesions of gastroenteropancreatic neuroendocrine neoplasms. Int J Surg Pathol 2021; 29 (05) 475-481
• 36 Chung YR, Jang MH, Park SY, Gong G, Jung WH. Korean Breast Pathology Ki-67 Study Group. Interobserver variability of Ki-67 measurement in breast cancer. J Pathol Transl Med 2016; 50 (02) 129-137
• 37 Yamamoto S, Chishima T, Mastubara Y. et al. Variability in measuring the Ki-67 labeling index in patients with breast cancer. Clin Breast Cancer 2015; 15 (01) e35-e39
• 38 Feng M, Deng Y, Yang L. et al. Automated quantitative analysis of Ki-67 staining and HE images recognition and registration based on whole tissue sections in breast carcinoma. Diagn Pathol 2020; 15 (01) 65
• 39 Wang HY, Li ZW, Sun W. et al. Automated quantification of Ki-67 index associates with pathologic grade of pulmonary neuroendocrine tumors. Chin Med J (Engl) 2019; 132 (05) 551-561